XOMA Appoints Alan M. Solinger, M.D. as Vice President of Clinical Immunology
Thursday July 28, 12:14 pm ET
BERKELEY, Calif.--(BUSINESS WIRE)--July 28, 2005--XOMA Ltd. (Nasdaq:XOMA - News), a biopharmaceutical company developing antibody and protein-based drugs for cancer, immunological disorders and infectious diseases, today announced the appointment of Alan M. Solinger, M.D., as Vice President of Clinical Immunology.
ADVERTISEMENT
"Alan brings significant clinical and commercial experience in the areas of immunology and rheumatology to XOMA to complement our existing expertise resulting from our key role in the development of RAPTIVA®," said John L. Castello, chairman, president, and chief executive officer of XOMA. "Immunological disorders continue to be an important focus of our pipeline and we look forward to enhancing XOMA's clinical capabilities in this area to support our internal and collaborative programs under Alan's leadership."
Before joining XOMA, Dr. Solinger was director of clinical research at Amgen, Inc. from 2000-2005. As director of clinical research at Amgen, he participated in the design of the clinical and commercial strategies for marketed products Enbrel® (Etanercept) and Kineret® (Anakinra), and for other late-stage products. From 1998-2000, Dr. Solinger was medical director for Parexel International, Inc., where he was responsible for the ongoing monitoring and consulting of over 30 immunology/rheumatology/HIV clinical trials for Paraxel worldwide. Prior to that, he held clinical research management positions at IDEC and CIBA-GEIGY.
Dr. Solinger received his bachelor's degree in chemical biology from Columbia University and his medical doctorate from the University of Cincinnati College of Medicine. He completed his internship and residency in internal medicine at the University of Missouri Medical Center, in Columbia, MO. Additionally, he has served as a research associate for the National Institutes of Health (NIH), Lab of Immunology and as a fellow at the University of California, San Francisco, Division of Rheumatology-Clinical Immunology. Currently a clinical professor of medicine at the Division of Rheumatology of the University of California, Los Angeles, College of Medicine, Dr. Solinger is also a frequent lecturer and has authored or co-authored more than 100 scientific abstracts, papers, case studies and editorials.
About XOMA
XOMA develops antibody and other protein-based biopharmaceuticals for commercialization, with a therapeutic focus on cancer, immune disorders and infectious diseases. XOMA has a royalty interest in RAPTIVA®, a product marketed worldwide that was developed in collaboration with Genentech. The Company pipeline includes proprietary products along with collaborative product development programs. For more information about XOMA's product pipeline and antibody product development capabilities and technologies, please visit XOMA's website at xoma.com. |
